ACE-2223 in Neurodegenerative Diseases: ACTRN12626000231347 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
96
Planned enrollment
Timing not reported
Primary-completion proxy
Executive view
ACTRN12626000231347 evaluates ACE-2223 in Neurodegenerative Diseases. The disclosed sponsor is Acelot, Inc., the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ACTRN12626000231347 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Neurodegenerative Diseases landscape. Drug & Asset MCP drug_fetch was queried for ACE-2223, while Company & Deal Intelligence MCP organization_fetch was queried for Acelot, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| ACTRN12626000231347 | ACE-2223 | Phase 1 / Recruiting | Acelot, Inc. | Australia | Timing not reported | |
| NCT07589764 | Beta-Hydroxy-Beta-Methylbutyrate | Phase 1 / Not yet recruiting | Duke University | United States | ALS Functional Rating Scale, Revised (ALSFRS-R) Baseline, month 3, month 9 | 2027-10-01 |
| NCT07571174 | LY-4256984 | Phase 1 / Recruiting | Eli Lilly & Co. | Canada, Netherlands, Belgium, Germany, Spain | Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to… Baseline Up to Week 96 | 2029-06-01 |
| ACTRN12626000233325 | ACE-2223 | Phase 1 / Not yet recruiting | Acelot, Inc. | Australia | Timing not reported | |
| NCT07423494 | nL-CHCHD-001 | Phase 1/2 / Not yet recruiting | n-Lorem Foundation | United States | Clinical Functioning Baseline to 12 Months | 2027-03-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
ACTRN12626000231347 is a Phase 1, recruiting study with 96 planned participants. Allocation is Randomised controlled trial, masking is Blinded (masking used), and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: Part A (SAD) Safety and tolerability of single ascending doses of orally administered ACE-2223-1 in healthy adults will be assessed as a composite outcome based on treatment-emergent adverse events (TEAEs), vital signs, physical examinations, clinical laboratory tests, and safety EEG and ECG assessments.[TEAEs will be monitored throughout the study. Examples of possible adverse events may include headache, dizziness, gastrointestinal symptoms (e.g., nausea), fatigue, changes in vital signs, or abnormal laboratory findings. Adverse events will be identified through participant self-report, investigator questionin….
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 96 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Neurodegenerative Diseases. These records do not establish direct evidence for ACTRN12626000231347 unless the registration number matches.
A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral S…
Phase 1/2; n=8; AE = 3 participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05683860
Expansion and Infusion of T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Phase 1; n=3; Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.0) & Medical Dictionary for Regulatory Activities (MedDRA). = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT03241784
Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis
Phase 2; n=68; Drug-related adverse events = 4.3 % ; Drug-related adverse events = 20.0 % Source: https://pubmed.ncbi.nlm.nih.gov/41837970/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “ACE-2223.” The report therefore avoids inferring modality, target or global development stage from the name alone.
Acelot, Inc. is indexed in United States with the website http://www.acelot.com. Operates as a biotechnology company focused on AI-driven drug discovery and development of therapies for neurodegenerative diseases The record lists 3 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether ACE-2223 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: ACTRN12626000231347
Protocol source: https://anzctr.org.au/ACTRN12626000231347.aspx
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
ACE-2223 in Neurodegenerative Diseases is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
